皓元医药(688131.SH):遭弃购5252股 由主承销商包销
格隆汇6月2日丨皓元医药(688131.SH)发布首次公开发行股票并在科创板上市发行结果公告,保荐机构(主承销商)根据上海证券交易所和中国结算上海分公司提供的数据,对本次战略配售、网上、网下发行的新股认购情况进行了统计,结果如下:
(一)战略配售情况
本次发行的战略配售由保荐机构相关子公司跟投和发行人的高级管理人员与核心员工专项资产管理计划组成。跟投机构为民生证券投资有限公司,发行人的高级管理人员与核心员工专项资产管理计划为皓元医药战略配售1号集合资产管理计划。缴款认购结果如下:
1、民生证券投资有限公司
(1)缴款认购股数(股):744,000;
(2)缴款认购金额(元):48,352,560.00;
(3)限售期:24个月。
2、皓元医药战略配售1号集合资产管理计划
(1)缴款认购股数(股):1,851,031;
(2)缴款认购金额(元):120,298,504.69;
(3)新股配售经纪佣金(元):601,492.52;
(4)限售期:12个月
(二)网上新股认购情况
(1)网上投资者缴款认购的股份数量(股):6,338,248;
(2)网上投资者缴款认购的金额(元):411,922,737.52;
(3)网上投资者放弃认购数量(股):5,252;
(4)网上投资者放弃认购金额(元):341,327.48。
(三)网下新股认购情况
(1)网下投资者缴款认购的股份数量(股):9,661,469;
(2)网下投资者缴款认购的金额(元):627,898,870.31;
(3)网下投资者放弃认购数量(股):0;
(4)网下投资者放弃认购金额(元):0;
(5)网下投资者缴纳的新股配售经纪佣金(元):3,139,502.89。
网上、网下投资者放弃认购股数全部由保荐机构(主承销商)包销,保荐机构(主承销商)包销股份的数量为5252股,包销金额为34.132748万元,包销股份的数量约占扣除战略配售数量后本次公开发行股票总量的0.0328%,包销股份的数量约占本次公开发行股票总量的0.0282%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.